MIRA PHARMACEUTICALS, INC. (MIRA)

MIRA Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies for neurologic, inflammatory, and metabolic diseases, with a lead program (Ketamir-2) in Phase 1 testing for chemotherapy-induced peripheral neuropathy and additional programs in development for chronic inflammatory pain and obesity/nicotine addiction. The company's approach involves modifying existing biological compounds to create safer, orally available drug candidates.